ABL Diagnostics signed a Channel Partner Agreement with Illumina to offer, combined with ABL Diagnostics’ DeepChek™ products, on the iSeq™ 100 and MiSeq™ next-generation sequencing platforms to microbiology laboratories in mainland France Belgium and Luxembourg

ABL Diagnostics is pleased to announce a strategic collaboration with Illumina through an international Channel Partners Agreement conferring to ABL Diagnostics the ability to offer, combined with ABL Diagnostics’ products (DeepChek), Illumina Next Generation Sequencing (iSeq™ 100 and MiSeq™) instruments and services to microbiology laboratories in mainland France, Belgium and Luxembourg, willing to implement robust genotyping by sequencing solutions covering many infectious diseases (HIV, Tuberculosis, Viral Hepatitis, CMV, HPV…).